Lucien A. Aarden mostly deals with Immunology, Internal medicine, Antibody, Molecular biology and Monoclonal antibody. His work on Immunology deals in particular with Arthritis, Adalimumab, Monoclonal, Rheumatoid arthritis and Tumor necrosis factor alpha. As part of one scientific family, he deals mainly with the area of Internal medicine, narrowing it down to issues related to the Gastroenterology, and often Multiple organ dysfunction syndrome.
His work deals with themes such as Clinical state and Immune system, which intersect with Antibody. His research in Molecular biology intersects with topics in Cell culture, Lymphokine, DNA, Mitochondrial DNA and Serology. His Monoclonal antibody research is multidisciplinary, relying on both Biotinylation, Recombinant DNA, Virology, Synovial fluid and Horseradish peroxidase.
His primary areas of investigation include Immunology, Molecular biology, Antibody, Internal medicine and Monoclonal antibody. His Immunology research focuses on Cytokine, Rheumatoid arthritis, Adalimumab, Antigen and Interleukin 6. The Molecular biology study combines topics in areas such as T cell, IL-2 receptor, Cell culture and DNA.
Antibody is often connected to Radioimmunoassay in his work. His research integrates issues of Gastroenterology and Endocrinology in his study of Internal medicine. His study looks at the intersection of Monoclonal antibody and topics like Receptor with Interleukin-6 receptor and CD32.
His scientific interests lie mostly in Immunology, Adalimumab, Antibody, Monoclonal antibody and Rheumatoid arthritis. Immunology connects with themes related to Internal medicine in his study. His Adalimumab research includes elements of Area under the curve, Arthritis, Monoclonal, Infliximab and Prospective cohort study.
His Antibody research incorporates elements of Interleukin 3, Interleukin 20, Interleukin 5 and Interleukin 6. His Monoclonal antibody study combines topics in areas such as Molecular biology, Pharmacokinetics and In vitro. His studies in Rheumatoid arthritis integrate themes in fields like Connective tissue disease and Immunopathology.
Lucien A. Aarden spends much of his time researching Immunology, Adalimumab, Rheumatoid arthritis, Internal medicine and Antibody. Monoclonal antibody and Immunogenicity are the primary areas of interest in his Immunology study. Lucien A. Aarden has researched Adalimumab in several fields, including Immunopathology and Arthritis.
His Rheumatoid arthritis research incorporates themes from Connective tissue disease and Infliximab. His biological study deals with issues like Gastroenterology, which deal with fields such as Surgery and Methotrexate. His Antibody research integrates issues from Proinflammatory cytokine, Immune system and Cell biology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Production of hybridoma growth factor by human monocytes.
Lucien A. Aarden;Els R. De Groot;Otto L. Schaap;Peter M. Lansdorp.
European Journal of Immunology (1987)
Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways
S. J. H. Van Deventer;H. R. Buller;J. W. Ten Cate;L. A. Aarden.
Increased plasma levels of interleukin-6 in sepsis [see comments]
CE Hack;ER De Groot;RJ Felt-Bersma;JH Nuijens.
Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production.
T. C. T. M. Van Der Pouw Kraan;L. C. M. Boeije;R. J. T. Smeenk;J. Wijdenes.
Journal of Experimental Medicine (1995)
Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange
Marijn van der Neut Kolfschoten;Janine Schuurman;Mario Losen;Wim K. Bleeker.
IMMUNOLOGY OF DNA. III. CRITHIDIA LUCILIAE, A SIMPLE SUBSTRATE FOR THE DETERMINATION OF ANTI‐dsDNA WITH THE IMMUNOFLUORESCENCE TECHNIQUE*
L. A. Aarden;Els R. de Groot;T. E. W. Feltkamp.
Annals of the New York Academy of Sciences (1975)
Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up.
Geertje M. Bartelds;Charlotte L. M. Krieckaert;Michael T. Nurmohamed;Pauline A. van Schouwenburg.
Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis
Geertje M Bartelds;Carla A Wijbrandts;Michael T Nurmohamed;Steven Stapel.
Annals of the Rheumatic Diseases (2007)
Functional discrimination between interleukin 6 and interleukin 1
Maarten Helle;Leonie Boeije And and;Lucien A. Aarden.
European Journal of Immunology (1988)
Serum levels of interleukin-6 and acute phase responses.
M.W.N. Nijsten;E.R. De Groot;H.J. Ten Duis;H.J. Klasen.
The Lancet (1987)
Profile was last updated on December 6th, 2021.
Research.com Ranking is based on data retrieved from the Microsoft Academic Graph (MAG).
The ranking d-index is inferred from publications deemed to belong to the considered discipline.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: